M360 ASPIRE
LIVE

Serial Number

99491161

Owner

Medicines360

Attorney

Cecily Anne O'Regan

Filing Date

Nov 11, 2025

Add to watchlist:

No watchlists yet
View on USPTO

M360 ASPIRE Trademark

Serial Number: 99491161

M360 ASPIRE is a trademark filed by Medicines360 on November 11, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Medicines360 (29 trademarks)

353 Sacramento Street
San Francisco, CA 94111

Entity Type: 99

Trademark Details

Filing Date

November 11, 2025

Registration Date

Not Registered

Goods & Services

Providing medical and scientific research information in the field of women’s health, men’s health, cardiology, endocrinology, gynecology, immunology, oncology, ophthalmology, hematology, infectious disease, gastroenterology, neurology, urology, dermatology, reproduction, infertility, pregnancy, contraception, proteomics and diabetes; Providing online non-downloadable software for medical diagnostic testing or treatment; Software as a service (SAAS) services featuring software for medical assessment, diagnostic testing or treatment; Providing online non-downloadable software, for medical testing, reports for risk prediction and classification and information in the field of maternal health and health conditions during pregnancy and labor

Providing medical information in the field of women’s health, men’s health, cardiology, endocrinology, gynecology, immunology, oncology, ophthalmology, hematology, infectious disease, gastroenterology, neurology, urology, dermatology, reproduction, infertility, pregnancy, contraception, proteomics and diabetes; Medical diagnostic testing, monitoring and reporting services; providing medical information in the field of medical testing, risk prediction and classification of maternal health conditions and health conditions during pregnancy and labor

Reagents and assays for scientific and research use

Medical reagents and assays; Medical diagnostic reagents and assays; reagents and assays for use in treating, monitoring, testing, analyzing and detecting medical conditions, diseases and disorders in the field of women’s health, men’s health, cardiology, endocrinology, gynecology, immunology, oncology, ophthalmology, hematology, infectious disease, gastroenterology, neurology, urology, dermatology, reproduction, infertility, pregnancy, contraception, proteomics and diabetes; diagnostic biomarker reagents and assays for medical purposes

Promoting awareness of and organizing and developing projects to support women’s health

Educational services, including conducting classes, seminars, conferences, workshops, and online webinars for physicians and other medical service providers to provide instruction on the use of software and medical reagents and assays, and distribution of training materials in connection therewith

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 29, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 29, 2026 XELR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 14, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 14, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 14, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 14, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 14, 2026 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 31, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 31, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 31, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 21, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 13, 2026 NWOS
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 12, 2026 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 12, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 12, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 12, 2026 REAP
APPLICATION FILING RECEIPT MAILED
Nov 11, 2025 MAFR
NEW APPLICATION ENTERED
Nov 11, 2025 NWAP